Philip Morris International (PMI) has dedicated significant resources to the development and scientific assessment of Reduced Risk Products (RRPs) with the ambition of providing smokers with less harmful alternatives to cigarettes.
Our research program is inspired by the practices of the pharmaceutical industry and includes fundamental research on tobacco related diseases, product development, methods to substantiate risk reduction and ways to assess the impact on population harm. We believe it is important to share our data to facilitate and encourage independent verification of methodologies and findings.
Between June 2016 and January 2018, PMI accepted proposals under an Investigator Initiated Studies (IIS) pilot program, to support external scientists to advance and verify RRP science. The IIS pilot program has now been discontinued. Nevertheless, approved investigator initiated studies that progress according to plan will be supported until completion. The list of studies, guidelines and terms and conditions are still available on this website.